Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Representative image of an oncology infusion and hearing assessment setting, illustrating Acousia Therapeutics’ bimokalner research into preventing cisplatin-induced hearing loss in cancer patients.
Pharma & Biotech

Acousia Therapeutics’ ACOU085 signal puts Kv7.4 activation in focus for hearing loss prevention

Read how Acousia Therapeutics’ bimokalner Phase 2a signal could reshape cisplatin hearing loss prevention in adults.

Read More
Representative image of hematology research and blood sample analysis, reflecting AbbVie’s long-term Venclexta data in first-line chronic lymphocytic leukemia treatment.
Pharma & Biotech

AbbVie’s Venclexta update puts long-term CLL treatment-free survival back in focus

Find out how AbbVie’s nine-year venetoclax CLL data could reshape fixed-duration treatment decisions and long-term leukemia care.

Read More
Representative image: A clinician discusses nerve pain research and treatment data with a patient, reflecting Lateral Pharma’s LanCL1 discovery and the search for new neuropathic pain drug targets.
Pharma & Biotech

Is Lateral Pharma’s pain platform quietly opening a new biotech battleground?

Find out how Lateral Pharma’s LanCL1 discovery could reshape neuropathic pain drug research and open a new biotech opportunity.

Read More
Representative image: A dermatologist discusses plaque psoriasis treatment with a patient, reflecting Akeso’s gumokimab approval and the intensifying IL-17 biologics race in China’s autoimmune disease market.
Pharma & Biotech

Why Akeso’s gumokimab approval could sharpen China’s psoriasis biologics race

Find out how Akeso’s gumokimab approval could reshape China’s psoriasis biologics market and IL-17 competition.

Read More
Pharma & Biotech

Why Blood Cancer United’s luveltamab move could change rare pediatric cancer access

Find out how Blood Cancer United’s luveltamab access move could reshape rare pediatric AML drug rescue models.

Read More
Representative image of autoimmune disease drug safety review as Amgen’s Tavneos scrutiny puts ANCA vasculitis treatment, FDA approval standards, liver risk, and rare disease evidence under sharper focus.
Pharma & Biotech

Amgen turns to Duke as FDA scrutiny puts Tavneos rare autoimmune disease role at risk

Find out how Amgen’s Tavneos data review could shape FDA withdrawal risk, liver safety scrutiny, and ANCA vasculitis care.

Read More
Representative image of neuroimmunology research as Sanofi’s riliprubart Phase 3 trial halt puts CIDP treatment, complement inhibition, and rare neurology drug development under sharper focus.
Pharma & Biotech

Sanofi riliprubart setback puts VITALIZE trial and CIDP strategy under sharper focus

Find out how Sanofi’s riliprubart Phase 3 trial halt could reshape CIDP drug development and complement inhibition strategy.

Read More
Representative image of oncology drug discovery as Parabilis Medicines’ IPO surge puts Helicon peptides, zolucatetide, desmoid tumors, and Wnt-driven cancer treatment under sharper focus.
Pharma & Biotech

Parabilis Medicines IPO boom raises the bar for zolucatetide clinical execution

Find out how Parabilis Medicines’ IPO surge could reshape investor appetite for Helicon peptides and Wnt-driven oncology drugs.

Read More
Representative image: An oncologist discusses colon cancer treatment options with a patient, reflecting Genentech’s Tecentriq Priority Review and the growing role of immunotherapy in stage III dMMR/MSI-H colon cancer care.
Pharma & Biotech

Why Genentech’s Tecentriq Priority Review could change adjuvant colon cancer treatment

Find out how Genentech’s Tecentriq Priority Review could reshape adjuvant treatment for stage III dMMR/MSI-H colon cancer.

Read More
Representative image of cardiovascular drug research as Kardigan’s planned Nasdaq IPO puts precision heart medicines, late-stage clinical trials, and biotech investor appetite under sharper focus.
Pharma & Biotech

Kardigan’s $1.4bn IPO plan tests investor appetite for late-stage cardiovascular biotech

Find out how Kardigan’s planned Nasdaq IPO could reshape precision cardiovascular drug development and biotech investor sentiment.

Read More